HEADER ONCOPROTEIN 22-MAR-19 6JOI TITLE CRYSTAL STRUCTURE OF PDGFRA T674I IN COMPLEX WITH CRENOLANIB BY CO- TITLE 2 CRYSTALLIZATION COMPND MOL_ID: 1; COMPND 2 MOLECULE: PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: PDGFR-ALPHA,ALPHA PLATELET-DERIVED GROWTH FACTOR RECEPTOR, COMPND 5 ALPHA-TYPE PLATELET-DERIVED GROWTH FACTOR RECEPTOR,CD140 ANTIGEN-LIKE COMPND 6 FAMILY MEMBER A,CD140A ANTIGEN,PLATELET-DERIVED GROWTH FACTOR ALPHA COMPND 7 RECEPTOR,PLATELET-DERIVED GROWTH FACTOR RECEPTOR 2,PDGFR-2; COMPND 8 EC: 2.7.10.1,2.7.10.1; COMPND 9 ENGINEERED: YES; COMPND 10 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PDGFRA, PDGFR2, RHEPDGFRA; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS PDGFRA, T674I, INHIBITOR, CRENOLANIB, ONCOPROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR L.LIANG,X.E.YAN,C.H.YUN REVDAT 2 22-NOV-23 6JOI 1 REMARK REVDAT 1 25-MAR-20 6JOI 0 JRNL AUTH L.LIANG,X.E.YAN JRNL TITL CRYSTAL STRUCTURE OF PDGFRA T674I IN COMPLEX WITH CRENOLANIB JRNL TITL 2 BY CO-CRYSTALLIZATION JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 3.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (DEV_2400: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.02 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.370 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 3 NUMBER OF REFLECTIONS : 7841 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.224 REMARK 3 R VALUE (WORKING SET) : 0.223 REMARK 3 FREE R VALUE : 0.244 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.090 REMARK 3 FREE R VALUE TEST SET COUNT : 399 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 47.0277 - 4.4380 1.00 2605 133 0.2093 0.2096 REMARK 3 2 4.4380 - 3.5229 1.00 2476 126 0.2104 0.2509 REMARK 3 3 3.5229 - 3.0777 0.96 2361 140 0.2882 0.3145 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.400 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 24.160 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.013 2460 REMARK 3 ANGLE : 1.502 3333 REMARK 3 CHIRALITY : 0.093 360 REMARK 3 PLANARITY : 0.008 411 REMARK 3 DIHEDRAL : 22.835 920 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6JOI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 28-MAR-19. REMARK 100 THE DEPOSITION ID IS D_1300011295. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-MAY-17 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRF REMARK 200 BEAMLINE : BL19U1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97776 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS3 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : HKL-3000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 7841 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.100 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 200 DATA REDUNDANCY : 6.300 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 13.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.34 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 5K5X REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.70 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.35 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M NACL, 0.1M TRIS PH 8.0, 15% PEG REMARK 280 4000, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 26.37850 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 51.85300 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.99600 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 51.85300 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 26.37850 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.99600 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 HIS A 527 REMARK 465 HIS A 528 REMARK 465 HIS A 529 REMARK 465 HIS A 530 REMARK 465 HIS A 531 REMARK 465 HIS A 532 REMARK 465 ASP A 533 REMARK 465 TYR A 534 REMARK 465 ASP A 535 REMARK 465 ILE A 536 REMARK 465 PRO A 537 REMARK 465 THR A 538 REMARK 465 THR A 539 REMARK 465 GLU A 540 REMARK 465 ASN A 541 REMARK 465 LEU A 542 REMARK 465 TYR A 543 REMARK 465 PHE A 544 REMARK 465 GLN A 545 REMARK 465 GLY A 546 REMARK 465 ALA A 547 REMARK 465 MET A 548 REMARK 465 ASP A 549 REMARK 465 LYS A 550 REMARK 465 GLN A 551 REMARK 465 LYS A 552 REMARK 465 PRO A 553 REMARK 465 ARG A 554 REMARK 465 TYR A 555 REMARK 465 GLU A 556 REMARK 465 ILE A 557 REMARK 465 ARG A 558 REMARK 465 TRP A 559 REMARK 465 ARG A 560 REMARK 465 VAL A 561 REMARK 465 ILE A 562 REMARK 465 GLU A 563 REMARK 465 SER A 564 REMARK 465 ILE A 565 REMARK 465 SER A 566 REMARK 465 PRO A 567 REMARK 465 ASP A 568 REMARK 465 SER A 767 REMARK 465 HIS A 768 REMARK 465 LYS A 769 REMARK 465 LYS A 770 REMARK 465 LYS A 771 REMARK 465 SER A 772 REMARK 465 MET A 773 REMARK 465 LEU A 774 REMARK 465 ASP A 775 REMARK 465 SER A 776 REMARK 465 GLU A 777 REMARK 465 VAL A 778 REMARK 465 LYS A 779 REMARK 465 ASN A 780 REMARK 465 LEU A 781 REMARK 465 LEU A 782 REMARK 465 SER A 783 REMARK 465 ASP A 784 REMARK 465 ASP A 785 REMARK 465 ASN A 786 REMARK 465 SER A 787 REMARK 465 GLU A 788 REMARK 465 ALA A 840 REMARK 465 ARG A 841 REMARK 465 ASP A 842 REMARK 465 ILE A 843 REMARK 465 MET A 844 REMARK 465 HIS A 845 REMARK 465 ASP A 846 REMARK 465 SER A 847 REMARK 465 ASN A 848 REMARK 465 TYR A 849 REMARK 465 VAL A 850 REMARK 465 SER A 851 REMARK 465 LYS A 852 REMARK 465 GLY A 853 REMARK 465 SER A 854 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 597 CG CD NE CZ NH1 NH2 REMARK 470 LYS A 833 NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 817 -13.59 78.72 REMARK 500 ASP A 818 57.02 -147.64 REMARK 500 ASP A 902 -169.90 -169.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 6T2 A 1001 DBREF 6JOI A 550 768 UNP P16234 PGFRA_HUMAN 550 696 DBREF 6JOI A 769 973 UNP P16234 PGFRA_HUMAN 769 973 SEQADV 6JOI HIS A 527 UNP P16234 EXPRESSION TAG SEQADV 6JOI HIS A 528 UNP P16234 EXPRESSION TAG SEQADV 6JOI HIS A 529 UNP P16234 EXPRESSION TAG SEQADV 6JOI HIS A 530 UNP P16234 EXPRESSION TAG SEQADV 6JOI HIS A 531 UNP P16234 EXPRESSION TAG SEQADV 6JOI HIS A 532 UNP P16234 EXPRESSION TAG SEQADV 6JOI ASP A 533 UNP P16234 EXPRESSION TAG SEQADV 6JOI TYR A 534 UNP P16234 EXPRESSION TAG SEQADV 6JOI ASP A 535 UNP P16234 EXPRESSION TAG SEQADV 6JOI ILE A 536 UNP P16234 EXPRESSION TAG SEQADV 6JOI PRO A 537 UNP P16234 EXPRESSION TAG SEQADV 6JOI THR A 538 UNP P16234 EXPRESSION TAG SEQADV 6JOI THR A 539 UNP P16234 EXPRESSION TAG SEQADV 6JOI GLU A 540 UNP P16234 EXPRESSION TAG SEQADV 6JOI ASN A 541 UNP P16234 EXPRESSION TAG SEQADV 6JOI LEU A 542 UNP P16234 EXPRESSION TAG SEQADV 6JOI TYR A 543 UNP P16234 EXPRESSION TAG SEQADV 6JOI PHE A 544 UNP P16234 EXPRESSION TAG SEQADV 6JOI GLN A 545 UNP P16234 EXPRESSION TAG SEQADV 6JOI GLY A 546 UNP P16234 EXPRESSION TAG SEQADV 6JOI ALA A 547 UNP P16234 EXPRESSION TAG SEQADV 6JOI MET A 548 UNP P16234 EXPRESSION TAG SEQADV 6JOI ASP A 549 UNP P16234 EXPRESSION TAG SEQADV 6JOI ILE A 674 UNP P16234 THR 674 ENGINEERED MUTATION SEQRES 1 A 375 HIS HIS HIS HIS HIS HIS ASP TYR ASP ILE PRO THR THR SEQRES 2 A 375 GLU ASN LEU TYR PHE GLN GLY ALA MET ASP LYS GLN LYS SEQRES 3 A 375 PRO ARG TYR GLU ILE ARG TRP ARG VAL ILE GLU SER ILE SEQRES 4 A 375 SER PRO ASP GLY HIS GLU TYR ILE TYR VAL ASP PRO MET SEQRES 5 A 375 GLN LEU PRO TYR ASP SER ARG TRP GLU PHE PRO ARG ASP SEQRES 6 A 375 GLY LEU VAL LEU GLY ARG VAL LEU GLY SER GLY ALA PHE SEQRES 7 A 375 GLY LYS VAL VAL GLU GLY THR ALA TYR GLY LEU SER ARG SEQRES 8 A 375 SER GLN PRO VAL MET LYS VAL ALA VAL LYS MET LEU LYS SEQRES 9 A 375 PRO THR ALA ARG SER SER GLU LYS GLN ALA LEU MET SER SEQRES 10 A 375 GLU LEU LYS ILE MET THR HIS LEU GLY PRO HIS LEU ASN SEQRES 11 A 375 ILE VAL ASN LEU LEU GLY ALA CYS THR LYS SER GLY PRO SEQRES 12 A 375 ILE TYR ILE ILE ILE GLU TYR CYS PHE TYR GLY ASP LEU SEQRES 13 A 375 VAL ASN TYR LEU HIS LYS ASN ARG ASP SER PHE LEU SER SEQRES 14 A 375 HIS LYS LYS LYS SER MET LEU ASP SER GLU VAL LYS ASN SEQRES 15 A 375 LEU LEU SER ASP ASP ASN SER GLU GLY LEU THR LEU LEU SEQRES 16 A 375 ASP LEU LEU SER PHE THR TYR GLN VAL ALA ARG GLY MET SEQRES 17 A 375 GLU PHE LEU ALA SER LYS ASN CYS VAL HIS ARG ASP LEU SEQRES 18 A 375 ALA ALA ARG ASN VAL LEU LEU ALA GLN GLY LYS ILE VAL SEQRES 19 A 375 LYS ILE CYS ASP PHE GLY LEU ALA ARG ASP ILE MET HIS SEQRES 20 A 375 ASP SER ASN TYR VAL SER LYS GLY SER THR PHE LEU PRO SEQRES 21 A 375 VAL LYS TRP MET ALA PRO GLU SER ILE PHE ASP ASN LEU SEQRES 22 A 375 TYR THR THR LEU SER ASP VAL TRP SER TYR GLY ILE LEU SEQRES 23 A 375 LEU TRP GLU ILE PHE SER LEU GLY GLY THR PRO TYR PRO SEQRES 24 A 375 GLY MET MET VAL ASP SER THR PHE TYR ASN LYS ILE LYS SEQRES 25 A 375 SER GLY TYR ARG MET ALA LYS PRO ASP HIS ALA THR SER SEQRES 26 A 375 GLU VAL TYR GLU ILE MET VAL LYS CYS TRP ASN SER GLU SEQRES 27 A 375 PRO GLU LYS ARG PRO SER PHE TYR HIS LEU SER GLU ILE SEQRES 28 A 375 VAL GLU ASN LEU LEU PRO GLY GLN TYR LYS LYS SER TYR SEQRES 29 A 375 GLU LYS ILE HIS LEU ASP PHE LEU LYS SER ASP HET 6T2 A1001 33 HETNAM 6T2 1-(2-{5-[(3-METHYLOXETAN-3-YL)METHOXY]-1H-BENZIMIDAZOL- HETNAM 2 6T2 1-YL}QUINOLIN-8-YL)PIPERIDIN-4-AMINE HETSYN 6T2 CRENOLANIB FORMUL 2 6T2 C26 H29 N5 O2 FORMUL 3 HOH *16(H2 O) HELIX 1 AA1 ASP A 576 LEU A 580 5 5 HELIX 2 AA2 PRO A 589 ASP A 591 5 3 HELIX 3 AA3 ARG A 634 GLY A 652 1 19 HELIX 4 AA4 LEU A 682 ASN A 689 1 8 HELIX 5 AA5 THR A 791 LYS A 812 1 22 HELIX 6 AA6 PRO A 858 MET A 862 5 5 HELIX 7 AA7 ALA A 863 ASP A 869 1 7 HELIX 8 AA8 THR A 873 SER A 890 1 18 HELIX 9 AA9 ASP A 902 GLY A 912 1 11 HELIX 10 AB1 THR A 922 TRP A 933 1 12 HELIX 11 AB2 GLU A 936 ARG A 940 5 5 HELIX 12 AB3 SER A 942 ASN A 952 1 11 HELIX 13 AB4 PRO A 955 SER A 972 1 18 SHEET 1 AA1 5 LEU A 593 SER A 601 0 SHEET 2 AA1 5 LYS A 606 TYR A 613 -1 O THR A 611 N VAL A 594 SHEET 3 AA1 5 VAL A 621 MET A 628 -1 O MET A 622 N ALA A 612 SHEET 4 AA1 5 TYR A 671 GLU A 675 -1 O ILE A 674 N ALA A 625 SHEET 5 AA1 5 LEU A 660 CYS A 664 -1 N GLY A 662 O ILE A 673 SHEET 1 AA2 3 GLY A 680 ASP A 681 0 SHEET 2 AA2 3 VAL A 824 LEU A 826 -1 O LEU A 826 N GLY A 680 SHEET 3 AA2 3 VAL A 832 ILE A 834 -1 O LYS A 833 N LEU A 825 SITE 1 AC1 10 LEU A 599 GLU A 675 TYR A 676 CYS A 677 SITE 2 AC1 10 PHE A 678 TYR A 679 GLY A 680 ARG A 822 SITE 3 AC1 10 LEU A 825 ASP A 836 CRYST1 52.757 73.992 103.706 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.018955 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013515 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009643 0.00000